NASDAQ:BIOL BIOLASE (BIOL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About BIOLASE Stock (NASDAQ:BIOL) Get BIOLASE alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume2.58 million shsMarket Capitalization$581 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BIOLASE, Inc. develops, manufactures and markets dental laser systems and related products for dentists and other oral health professionals. Its technology is designed to support a range of soft-tissue and hard-tissue procedures, including restorative, surgical, periodontal and endodontic treatments. The company’s product portfolio has included the Waterlase system, which uses a combination of laser energy, water and air for dental procedures, as well as the Epic line of diode lasers for soft-tissue applications. BIOLASE has also offered handpieces, accessories, supplies, training and other services intended to support the use of its laser platforms in dental practices. Founded in 1984, BIOLASE historically served customers in the United States and international markets through direct sales and distribution channels. The company was headquartered in California and focused on expanding the adoption of laser-based dentistry as an alternative or complement to conventional dental instruments. BIOLASE filed for Chapter 11 bankruptcy protection in 2024, and its subsequent corporate and operating status may differ from its historical business profile.AI Generated. May Contain Errors. Read More Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIOL Stock News HeadlinesBIOLASE and MegaGen America Expand Waterlase Foundations Training to Three U.S. Education CentersAugust 20, 2026 | tmcnet.comBIOLASE and MegaGen America Launch U.S. Commercial Collaboration to Advance "More Brilliant Dentistry Together"July 22, 2026 | finance.yahoo.comThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO as soon as this fall. TradeSmith CEO Keith Kaplan says chasing the next hot IPO isn't necessary. His AI-driven system, built on a platform pioneered by Google, ranks every stock in the S&P 500 and narrows the list to just five names to hold each month. Backtests show the Top Five Stocks outperformed the S&P 500 by 4x in August alone.October 10 at 1:00 AM | TradeSmith (Ad)MegaGen and BIOLASE Invest Nearly $1 Million to Expand Manufacturing Infrastructure at Corona, California FacilityJune 25, 2026 | prnewswire.comBIOLASE Showcases Advanced YSGG Laser Solutions for Periodontal and Implant Care at GNYDM 2025November 25, 2025 | finance.yahoo.comBIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025October 14, 2025 | prnewswire.comBIOLASE MG LLC: BIOLASE Emerges Stronger Than Ever Under New Ownership by MegaGen ImplantSeptember 10, 2025 | finanznachrichten.deBIOLASE Emerges Stronger Than Ever Under New Ownership by MegaGen ImplantSeptember 10, 2025 | prnewswire.comSee More Headlines BIOL Stock Analysis - Frequently Asked Questions How were BIOLASE's earnings last quarter? BIOLASE, Inc. (NASDAQ:BIOL) announced its earnings results on Wednesday, November, 10th. The medical technology company reported ($50.00) earnings per share for the quarter, beating the consensus estimate of ($75.00) by $25.00. The medical technology company had revenue of $9.53 million for the quarter. BIOLASE had a negative trailing twelve-month return on equity of 1,782.73% and a negative net margin of 41.65%. When did BIOLASE's stock split? Shares of BIOLASE reverse split on Friday, July 28th 2023.The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of BIOLASE? Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some other companies that BIOLASE investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), SNDL (SNDL), Zomedica (ZOM), NIO (NIO), Exela Technologies (XELA) and Ocugen (OCGN). Company Calendar Last Earnings11/10/2021Today10/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CIK811240 Webwww.biolase.com Phone(949) 361-1200Fax949-273-6677Employees160Year Founded1987Profitability EPS (Trailing Twelve Months)($14.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.63 million Net Margins-41.65% Pretax Margin-41.56% Return on Equity-1,782.73% Return on Assets-55.31% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.36 Sales & Book Value Annual Sales$48.83 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / BookN/AMiscellaneous Outstanding Shares33,407,000Free Float33,317,000Market Cap$581 thousand OptionableNot Optionable Beta0.67 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BIOL) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BIOLASE With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
